BlackRock Health Sciences Opps Inv A holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
BlackRock Health Sciences Opportunities Portfolio Investor A Shares SHSAX
- NAV / 1-Day Return $64.28 / +1.73 %
- Fund Size $6.2B
- Adjusted Expense Ratio 1.110%
- Net Expense Ratio 1.100%
- Fee Level: Distribution Below Average
- Share Class Type Front Load
- Morningstar Category Health
- Equity Style Box (Funds) Large Blend
- Minimum Initial Investment $1,000
- Investment Status Open
- TTM Yield 0.26%
- Turnover Ratio 49%
Morningstar’s Analysis SHSAX
Will SHSAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 53.3
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 11.92 | 760M | Healthcare |
Johnson & Johnson | 8.03 | 512M | Healthcare |
Merck & Co Inc | 5.56 | 355M | Healthcare |
AbbVie Inc | 5.07 | 323M | Healthcare |
Thermo Fisher Scientific Inc | 4.41 | 281M | Healthcare |
UnitedHealth Group Inc | 4.33 | 276M | Healthcare |
Gilead Sciences Inc | 4.09 | 261M | Healthcare |
Amgen Inc | 3.98 | 254M | Healthcare |
Vertex Pharmaceuticals Inc | 3.33 | 212M | Healthcare |
Abbott Laboratories | 2.61 | 167M | Healthcare |